BioTuesdays

Tag - H.C. Wainwright

BioCardia

HCW starts BioCardia at buy; PT $9

H.C Wainwright initiated coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and price target of $9. The stock closed at $1.71 on Dec. 17. BioCardia is a clinical-stage company focused on the development of cell...

89bio

HCW starts 89bio at buy; PT $46

H.C. Wainwright launched coverage of 89bio (NADAQ:ETNB) with a “buy” rating and price target of $46. The stock closed at $11.48 on Dec. 17. 89bio is a clinical-stage biopharmaceutical company focused on the development...

Vor Logo

HCW starts Vor Biopharma at buy; PT $26

H.C. Wainwright initiated coverage of Vor Biopharma (NASDAQ:VOR) with a “buy” rating and $26 price target. The stock closed at $12.13 on Dec. 16. Vor is a clinical-stage cell therapy company focused on developing...

Virios Therapeutics

HCW starts Virios Therapeutics at buy; PT $12

H.C. Wainwright initiated coverage of Virios Therapeutics (NASDAQ:VIRI) with a “buy” rating and price target of $12. The stock closed at $4.58 on Dec. 14. Virios is a clinical-stage biotech company developing a novel...

Gemini Therapeutics

HCW starts Gemini Therapeutics at buy; PT $20

H.C. Wainwright launched coverage of Gemini Therapeutics (NASDAQ:GMTX) with a “buy” rating and $20 price target. The stock closed at $2.43 on Dec. 14. Gemini is developing precision medicines for the treatment of...

Delcath-Systems-Inc

HCW starts Delcath Systems at buy; PT $25

H.C. Wainwright initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and 12-month price target of $25. The stock closed at $8.02 on Dec. 9. Delcath is a clinical-stage interventional oncology company...

Foghorn Therapeutics

HCW starts Foghorn Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...

PharmaCyte Logo

HCW starts PharmaCyte Biotech at neutral

H.C. Wainwright initiated coverage of PharmaCyte Biotech (NASDAQ:PMCB) with a “neutral” rating without a price target, as “we await the FDA’s clinical hold to be lifted.” The stock closed at $2.93 on Oct. 5. “Once...

Pliant Therapeutics

HCW starts Pliant Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a “buy” rating and $45 price target. The stock closed at $16.81 on Nov. 2. Pliant is a clinical-stage biopharmaceutical company focused on the...

biophytis

HCW starts Biophytis at buy; PT $15

H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.